Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC overexpression + IDH1 mutation
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
3417
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
IDH1 mutation + Chr del(1p) + Chr del(19q) (10)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)
IDH1 mutation + NTRK1 fusion (2)
IDH1 mutation + NTRK2 fusion (2)
IDH1 mutation + NTRK3 fusion (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
IDH wild-type + FGFR3 S249C + TP53 V73fs (1)
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)
IDH1 mutation + ATRX deletion + TP53 deletion (1)
IDH1 mutation + FGFR2 fusion (1)
IDH1 mutation + FGFR2 rearrangement (1)
IDH1 mutation + MGMT promoter methylation (1)
IDH1 mutation + TMB-L (1)
IDH1 mutation + WT1 overexpression (1)
IDH1 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)
IDH1 mutation + Chr del(1p) + Chr del(19q) (10)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)
IDH1 mutation + NTRK1 fusion (2)
IDH1 mutation + NTRK2 fusion (2)
IDH1 mutation + NTRK3 fusion (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
IDH wild-type + FGFR3 S249C + TP53 V73fs (1)
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)
IDH1 mutation + ATRX deletion + TP53 deletion (1)
IDH1 mutation + FGFR2 fusion (1)
IDH1 mutation + FGFR2 rearrangement (1)
IDH1 mutation + MGMT promoter methylation (1)
IDH1 mutation + TMB-L (1)
IDH1 mutation + WT1 overexpression (1)
IDH1 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC overexpression + IDH1 mutation
Acute Myelogenous Leukemia
MYC overexpression + IDH1 mutation
Acute Myelogenous Leukemia
enasidenib
Resistant: C3 – Early Trials
enasidenib
Resistant
:
C3
enasidenib
Resistant: C3 – Early Trials
enasidenib
Resistant
:
C3
MYC overexpression + IDH1 mutation
Acute Myelogenous Leukemia
MYC overexpression + IDH1 mutation
Acute Myelogenous Leukemia
ivosidenib
Resistant: C3 – Early Trials
ivosidenib
Resistant
:
C3
ivosidenib
Resistant: C3 – Early Trials
ivosidenib
Resistant
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.